Low-dose Rituximab Regimens in Chinese Adult Patients With Immune Thrombocytopenia

Summary

A comparative study with rituximab (100 mg weekly for 4 weeks and 375mg/m2 for once) shows low dose rituximab may be a useful alternative therapy in patients with ITP.The aim of this study is to compare the efficacy and tolerability of two different regimens of low doses rituximab for the treatment of adult patients with ITP.

Timeline

Start

2012-10

Primary completion

2015-10

Completion

2016-02

Publications

• Chen Y, Liu J, Dai J, Sun T, Qiao Z, Wang M, Zhou H, Zhou Z, Liu X, Fu R, Xue F, Liu W, Ju M, Dong H, Dai X, Gu W, Yang R, Zhang L. Long-term efficacy and safety of low-dose rituximab in immune thrombocytopenia: a multicentre, prospective, open-label, randomised controlled trial. Ann Hematol. 2026 Feb 26;105(4):140. doi: 10.1007/s00277-026-06908-2.

Drugs

Indications